CD8A and neoplasm: We show that following combined therapy there is an expansion in the frequency of CD8+ T-cells specific for the H2-Ld restricted epitope, AH1 (a peptide derived from an endogenous retroviral gene product; gp70) which is highly expressed on CT26 tumor cells [22, 23].